Akebia Therapeutics, Inc. (AKBA) stock
Close on Nov 12, 2026Market cap $138.00MP/E –Yield –
Akebia Therapeutics, Inc. saw revenue fall 12.4% to $197.20M over the twelve months to Sep 30, 2026. Operating income fell 274.9% to -$31.04M, moving the operating margin from 7.9% to -15.7%. Free cash flow was $13.86M, down 56.9% from a year earlier. At the latest close the market valued the company at $138.00M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $138.00M
- P/E ratio
- –
- Price to sales
- 0.70
- Price to book
- 6.77
- Dividend yield
- –
- Free cash flow yield
- 10.05%
Fundamentals
- Revenue
- $197.20M
- Net income
- -$44.56M
- EPS, diluted
- -$0.16
- Free cash flow
- $13.86M
- Book value per share
- $0.07
- Diluted shares
- 277M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $0.57
- Open
- $0.57
- Day's range
- $0.50 – $0.57
- Volume
- 4,084,293
- Average volume (20 days)
- 9,104,572
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.12
- 52-week range
- $0.36 – $1.89
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 88.9%
- Relative volume
- 0.53×
- WACC
- 9.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | AKBA | S&P 500 | Difference | AKBA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.0% | -2.7% | −34.3 pts | ||
| 3 months | -44.2% | -1.7% | −42.5 pts | ||
| Year to date | -69.1% | +11.9% | −81.0 pts | ||
| 1 year | -73.1% | +12.0% | −85.1 pts | ||
| 3 years | -44.2% | +78.2% | −122.4 pts | -17.7% | +21.2% |
| 5 years | -82.6% | +73.2% | −155.9 pts | -29.6% | +11.6% |
| 10 years | -94.3% | +309.6% | −404.0 pts | -24.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Akebia Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Results
About Akebia Therapeutics
Pharmaceutical Preparations
Akebia Therapeutics is a fully integrated biopharmaceutical company focused on developing and commercializing therapeutics for kidney disease and related conditions. Its primary commercial products are Vafseo (vadadustat), an oral hypoxia-inducible factor medicine for anemia associated with chronic kidney disease in adult dialysis patients, and Auryxia (ferric citrate), an oral treatment used for serum phosphorus control in dialysis-dependent chronic kidney disease and iron deficiency anemia in non-dialysis chronic kidney disease. The company's development pipeline includes mid-stage candidates such as praliciguat for focal segmental glomerulosclerosis and AKB-097 for complement-mediated kidney diseases, alongside early-stage programs exploring acute kidney injury, lung injury, and pediatric retinal disease. Its customers and target end-users encompass dialysis organizations, nephrologists, and adult patients undergoing kidney-related medical care.
Company profile, executives and historyAkebia Therapeutics stock: common questions
What is Akebia Therapeutics's stock price?
AKBA closed at $0.50 on Nov 12, 2026, down 13.20% on the day. Over the past 52 weeks it traded between $0.36 and $1.89.
What is Akebia Therapeutics's market cap?
Akebia Therapeutics was worth $138.00M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is AKBA's P/E ratio?
Akebia Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.16), so it has no meaningful P/E ratio.
How much revenue does Akebia Therapeutics make?
Akebia Therapeutics reported revenue of $197.20M for the twelve months to Sep 30, 2026, down 12.4% from a year earlier.
Does Akebia Therapeutics pay a dividend?
No. Akebia Therapeutics has not paid a cash dividend over the last twelve months.
When does Akebia Therapeutics report earnings next?
Akebia Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AKBA stock performed over the past year?
Including dividends, AKBA returned -73.1% over the past year, against +12.0% for the S&P 500.
How many AKBA shares are sold short?
27M shares were sold short at the latest FINRA report, 10.12% of the float, or 3.0 days of average trading volume.
Who are Akebia Therapeutics's competitors?
Companies most similar to Akebia Therapeutics by business, industry and size include AGIO, ARDX, AUPH, TVTX, AMRN.
See a number that looks wrong?